DK3514173T3 - DKK-1-antistoffer - Google Patents

DKK-1-antistoffer Download PDF

Info

Publication number
DK3514173T3
DK3514173T3 DK19156509.2T DK19156509T DK3514173T3 DK 3514173 T3 DK3514173 T3 DK 3514173T3 DK 19156509 T DK19156509 T DK 19156509T DK 3514173 T3 DK3514173 T3 DK 3514173T3
Authority
DK
Denmark
Prior art keywords
dkk
antibodies
Prior art date
Application number
DK19156509.2T
Other languages
English (en)
Inventor
Marcio Chedid
Ryan James Darling
Rachelle Jeanette Galvin
Barbara Anne Swanson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK3514173T3 publication Critical patent/DK3514173T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
DK19156509.2T 2009-04-10 2010-04-06 DKK-1-antistoffer DK3514173T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16841109P 2009-04-10 2009-04-10
EP15159780.4A EP2930184B1 (en) 2009-04-10 2010-04-06 Dkk-1 antibodies

Publications (1)

Publication Number Publication Date
DK3514173T3 true DK3514173T3 (da) 2021-08-02

Family

ID=42199718

Family Applications (3)

Application Number Title Priority Date Filing Date
DK19156509.2T DK3514173T3 (da) 2009-04-10 2010-04-06 DKK-1-antistoffer
DK15159780.4T DK2930184T3 (da) 2009-04-10 2010-04-06 Dkk-1-antistoffer
DK10712681.5T DK2417158T4 (da) 2009-04-10 2010-04-06 Dkk-1-antistoffer

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK15159780.4T DK2930184T3 (da) 2009-04-10 2010-04-06 Dkk-1-antistoffer
DK10712681.5T DK2417158T4 (da) 2009-04-10 2010-04-06 Dkk-1-antistoffer

Country Status (30)

Country Link
US (1) US8148498B2 (da)
EP (3) EP2417158B9 (da)
JP (1) JP5759977B2 (da)
KR (3) KR20110124364A (da)
CN (1) CN102388065B (da)
AR (1) AR075989A1 (da)
AU (1) AU2010234611B2 (da)
BR (1) BRPI1014157B1 (da)
CA (1) CA2758252C (da)
CY (3) CY1119399T1 (da)
DK (3) DK3514173T3 (da)
EA (1) EA021401B1 (da)
ES (3) ES2644244T3 (da)
HR (3) HRP20171400T1 (da)
HU (3) HUE043904T2 (da)
IL (1) IL214845A (da)
LT (3) LT2930184T (da)
ME (2) ME03378B (da)
MX (1) MX2011010707A (da)
NZ (1) NZ595011A (da)
PL (3) PL2930184T3 (da)
PT (3) PT2417158T (da)
RS (3) RS56505B1 (da)
SG (1) SG175244A1 (da)
SI (3) SI3514173T1 (da)
TR (1) TR201907261T4 (da)
TW (1) TWI546079B (da)
UA (1) UA103916C2 (da)
WO (1) WO2010117980A1 (da)
ZA (1) ZA201107256B (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR076668A1 (es) 2009-05-12 2011-06-29 Pfizer Anticuerpos especificos para dkk-1 y sus usos
ES2780398T3 (es) 2012-12-10 2020-08-25 Biogen Ma Inc Anticuerpo anti-antígeno 2 de células dendríticas sanguíneas y uso de los mismos
BR112017020610A2 (pt) 2015-05-18 2018-07-17 Lilly Co Eli Compostos de anticorpo biespecífico anti-dkk-1- anti-rankl
CA2996059A1 (en) * 2015-08-28 2017-03-09 Alector Llc Anti-siglec-7 antibodies and methods of use thereof
BR112018008904A2 (pt) 2015-11-03 2018-11-27 Janssen Biotech Inc anticorpos que se ligam especificamente a tim-3 e seus usos
MA46673A (fr) 2016-10-26 2019-09-04 Leap Therapeutics Inc Utilisation de la bêta-caténine en tant que biomarqueur pour traiter des cancers à l'aide d'un anticorps anti-dkk-1
CN113395978A (zh) * 2018-07-11 2021-09-14 动量制药公司 与靶向CTLA-4的工程化Fc-抗原结合结构域构建体有关的组合物和方法
CN112121147B (zh) * 2019-06-24 2023-07-04 中国人民解放军海军特色医学中心 多肽在治疗或预防骨髓瘤药物中的应用、多肽、核酸、药物及重组表达载体
CN114423459A (zh) 2019-09-19 2022-04-29 飞跃治疗公司 Dkk-1抑制剂用于治疗癌症的用途
CN114929275A (zh) * 2019-11-22 2022-08-19 飞跃治疗公司 使用dkk-1抑制剂治疗癌症的方法
KR102494042B1 (ko) * 2020-11-20 2023-02-07 주식회사 하울바이오 인간모유두세포의 성장을 촉진하는 항-dkk-1 항체 및 이의 용도
CN112592402B (zh) * 2020-12-02 2022-04-26 杭州奕安济世生物药业有限公司 抗dkk2抗体、包含该抗dkk2抗体的组合物及其用途
CA3206789A1 (en) * 2021-02-05 2022-08-11 Gregory A. Demopulos Biomarker for assessing the risk of developing acute covid-19 and post-acute covid-19
WO2023039249A1 (en) 2021-09-10 2023-03-16 Leap Therapeutics, Inc. Combination therapy
WO2024015463A1 (en) 2022-07-12 2024-01-18 Leap Therapeutics, Inc. Combination therapy
CN116589590B (zh) * 2023-03-21 2024-03-26 浙江大学 一种特异性抗异菌脲的单克隆抗体及其重组表达质粒

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69842225D1 (de) 1997-04-16 2011-05-26 Millennium Pharm Inc Zusammensetzung, umfassend einen Antikörper, der selektiv an ein cysteinreiches sekretiertes Protein (CRSP) bindet
DE19747418C1 (de) 1997-10-27 1999-07-15 Deutsches Krebsforsch Inhibitor-Protein des wnt-Signalwegs
US7446181B2 (en) * 1998-01-15 2008-11-04 Millennium Pharmaceuticals, Inc. Antibodies that bind human Dickkopf-1 proteins
PT1490386E (pt) 1998-03-10 2008-11-24 Genentech Inc Novos polipéptidos e ácidos nucleicos que os codificam
AU2001234944A1 (en) 2000-02-03 2001-08-14 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2002083921A2 (en) 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
US20040038860A1 (en) * 2002-05-17 2004-02-26 Allen Kristina M. Reagents and methods for modulating dkk-mediated interactions
JP2005512508A (ja) 2001-05-17 2005-05-12 ゲノム　セラピューティックス　コーポレーション Ｄｋｋ媒介性相互作用を変調する試薬および方法
US7308364B2 (en) * 2001-11-07 2007-12-11 The University Of Arkansas For Medical Sciences Diagnosis of multiple myeloma on gene expression profiling
CA2466483A1 (en) 2001-11-07 2003-07-03 John D. Shaughnessy Diagnosis prognosis and identification of potential therapeutic targets of multiple myeloma based on gene expression profiling
US7371736B2 (en) * 2001-11-07 2008-05-13 The Board Of Trustees Of The University Of Arkansas Gene expression profiling based identification of DKK1 as a potential therapeutic targets for controlling bone loss
US7642238B2 (en) * 2002-12-05 2010-01-05 Shaughnessy John D Molecular determinants of myeloma bone disease and uses thereof
US20050084494A1 (en) * 2003-05-21 2005-04-21 Darwin Prockop Inhibitors of Dkk-1
AU2004274861A1 (en) 2003-06-06 2005-03-31 Wyeth Methods and materials for identifying agents which modulate bone remodeling and agents identified thereby
WO2006015373A2 (en) * 2004-08-04 2006-02-09 Amgen Inc Antibodies to dkk-1
AR060017A1 (es) * 2006-01-13 2008-05-21 Novartis Ag Composiciones y metodos de uso para anticuerpos de dickkopf -1
JP2010517570A (ja) * 2007-02-08 2010-05-27 メルク・シャープ・エンド・ドーム・コーポレイション Ｄｋｋ−１に特異的な抗体
WO2010129752A1 (en) * 2009-05-07 2010-11-11 Novartis Ag Compositions and methods of use for binding molecules to dickkopf-1 or dickkopf-4 or both

Also Published As

Publication number Publication date
EP3514173B1 (en) 2021-06-23
CY1119399T1 (el) 2018-02-14
PT2930184T (pt) 2019-06-17
LT3514173T (lt) 2021-09-10
PL2417158T3 (pl) 2017-12-29
ES2728911T3 (es) 2019-10-29
ES2644244T3 (es) 2017-11-28
CY1124412T1 (el) 2022-07-22
CA2758252C (en) 2015-02-24
LT2417158T (lt) 2017-10-10
CN102388065B (zh) 2014-09-03
ZA201107256B (en) 2013-03-27
EA021401B1 (ru) 2015-06-30
JP2012523417A (ja) 2012-10-04
RS56505B1 (sr) 2018-02-28
PL2930184T3 (pl) 2019-10-31
SI2930184T1 (sl) 2019-06-28
DK2417158T4 (da) 2018-01-29
PT2417158T (pt) 2017-10-23
RS58612B1 (sr) 2019-05-31
AR075989A1 (es) 2011-05-11
DK2417158T3 (da) 2017-10-16
KR20110124364A (ko) 2011-11-16
HRP20171400T1 (hr) 2017-11-03
SI3514173T1 (sl) 2021-09-30
KR20140033523A (ko) 2014-03-18
CA2758252A1 (en) 2010-10-14
TW201100101A (en) 2011-01-01
ES2887176T3 (es) 2021-12-22
EP2930184A1 (en) 2015-10-14
HUE043904T2 (hu) 2019-09-30
EP3514173B8 (en) 2021-08-04
EP2417158B9 (en) 2017-12-06
EA201171237A1 (ru) 2012-04-30
TWI546079B (zh) 2016-08-21
PL3514173T3 (pl) 2022-01-17
EP2930184B1 (en) 2019-03-27
LT2930184T (lt) 2019-05-10
AU2010234611B2 (en) 2013-02-07
SI2417158T1 (sl) 2017-10-30
WO2010117980A1 (en) 2010-10-14
AU2010234611A1 (en) 2011-10-20
IL214845A0 (en) 2011-11-30
CY1121637T1 (el) 2020-07-31
BRPI1014157A2 (pt) 2020-09-29
KR101461362B1 (ko) 2014-11-13
US8148498B2 (en) 2012-04-03
HRP20211343T1 (hr) 2021-11-26
KR20140090273A (ko) 2014-07-16
ME03378B (me) 2020-01-20
ME02798B (me) 2018-01-20
RS62214B1 (sr) 2021-09-30
HRP20190643T1 (hr) 2019-05-31
BRPI1014157B1 (pt) 2022-01-18
HUE034625T2 (en) 2018-02-28
US20100260754A1 (en) 2010-10-14
EP3514173A1 (en) 2019-07-24
CN102388065A (zh) 2012-03-21
EP2417158B1 (en) 2017-08-02
DK2930184T3 (da) 2019-05-13
HUE055376T2 (hu) 2021-11-29
PT3514173T (pt) 2021-08-16
SG175244A1 (en) 2011-12-29
NZ595011A (en) 2013-05-31
EP2417158A1 (en) 2012-02-15
UA103916C2 (en) 2013-12-10
MX2011010707A (es) 2012-02-28
JP5759977B2 (ja) 2015-08-05
TR201907261T4 (tr) 2019-06-21
IL214845A (en) 2016-06-30

Similar Documents

Publication Publication Date Title
NO2020017I1 (no) Siponimod
HRP20171400T1 (hr) Protutijela protiv dkk-1
DK2462134T3 (da) N1-sulfonyl-5-fluorpyrimidinonderivater
BRPI1011005A2 (pt) anticorpos anti-epcam
BRPI1008827A2 (pt) deisobutenizador
BRPI1014968A2 (pt) subalargador
DE112010002728A5 (de) Turboinhalator
DE112009005323A5 (de) Hebelarmprüfmaschine
DE112009005462T8 (de) Lenkungsssteuervorrichtung
BR112012004964A2 (pt) girocóptero
BRPI1008070A2 (pt) tricianoboratos
BRPI1010159A2 (pt) bistuti
BR112012003616A2 (pt) metilpirroloprimidinacarboxamidas
DE112010002351A5 (de) Klemmorrichtung
DE112010003843T8 (de) Lastansteuervorrichtung
DE102009034429A8 (de) Flachantenne
DK2517018T3 (da) Biomarkører
AT506924A3 (de) Bauprojektor
AT508508A3 (de) Heuballenbohrer
FI20096331A0 (fi) Antibodin käyttö
TH0901003923A (th) แอนติบอดีหลายความจำเพาะ
TH0901003733A (th) องค์ประกอบเชิงภูมิคุ้มกัน
FI8641U1 (fi) Palkkikannake
DE112010002929A5 (de) Monomethoxy-hydroxy-benzylmalonate
FIU20090009U0 (fi) Savupiippuvaraaja